- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07941622
Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B Vaccine in Healthy Chinese Infants.
A Nested Phase 3, Randomized, Active-controlled, Open-label, 2-arm, Multicenter Study to Investigate the Immunogenicity and Safety of Sanofi's Hexavalent DTaP-IPV-HB-PRP~T Combined Vaccine Given at 2, 4, and 6 Months of Age Compared With DTaP-IPV//PRP~T Combined Vaccine (Pentaxim™) Given at 2, 4, and 6 Months of Age Administered With a Monovalent Hepatitis B Vaccine Given at 1 and 6 Months of Age to Healthy Chinese Infants Who Previously Received a Birth Dose of Monovalent Hepatitis B Vaccine
The purpose of this study is to measure the safety and immunogenicity of Hexaxim given at 2, 4, and 6 MoA compared with Pentaxim given at 2, 4, and 6 MoA plus a monovalent Hep B vaccine given at 1 and 6 MoA in healthy Chinese infants born to HBsAg seronegative mothers.
Study details include:
- The study duration per participant will be approximately 18 months.
- The study vaccines administration:
- Group 1: for the primary series vaccination, Hexaxim will be administered 3 doses at 2, 4, and 6 MoA.
- Group 2: for the primary series vaccination, Pentaxim will be administered 3 doses at 2, 4, and 6 MoA, and the monovalent Hep B vaccine will be administered at 1 and 6 MoA.
A tanulmány áttekintése
Állapot
Körülmények
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- 3. fázis
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Trial Transparency email recommended (Toll free for US & Canada)
- Telefonszám: option 6 800-633-1610
- E-mail: Contact-US@sanofi.com
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Aged 30 to 45 days on the day of inclusion, and have received 1 dose of monovalent Hep B vaccine
- Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥2.5 kg or born after a gestation period above 28 (>28 weeks) through 36 weeks with a birth weight ≥1.5 kg, and in both cases medically stable as assessed by the investigator
- Participants who are born to mothers with documented HBsAg seronegative status
- Informed consent form has been signed and dated by the parent(s) or other LAR
- Participant and parent/LAR are able to attend all scheduled visits and to comply with all study procedures
Exclusion Criteria:
- Known/suspected immunodeficiency; immunosuppressive therapy since birth; long-term systemic corticosteroid therapy
- History of diagnosis of Hepatitis B, diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b infection
- History of seizure or significant stable or progressive neurological disorders
- Known systemic hypersensitivity to any study intervention components, or history of a life-threatening reaction to study interventions or product with the same substances
- Known thrombocytopenia
- Bleeding disorder
- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
- Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (axillary temperature ≥37.5°C) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
- Any vaccine given since birth or planned receipt of any vaccine until 1 month after the completion of the primary series vaccination with the study interventions except for Bacille Calmette-Guérin (BCG) vaccine and meningococcal polysaccharide vaccine-A.
- Previous vaccination against D, T, pertussis, poliomyelitis, Hep B (except the dose of Hep B given at birth) or Haemophilus influenzae type b infections (since birth) with an investigational or marketed vaccine.
- Receipt of immune globulins, blood or blood-derived products
- Participation in another clinical study for a vaccine, drug, medical device, or medical procedure at the time of study enrollment or planned participation during the present study period.
- Known personal or maternal history of HIV or HCV seropositivity
- Being in an emergency setting
- Identified as a natural or adopted child of the Investigator/study site employee with direct involvement in the study
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Megelőzés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Egyetlen
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Group 1 (the investigational group)
Hexaxim at 2, 4 and 6 MoA |
Pharmaceutical form:Suspension for injection in a pre-filled syringe Route of administration:IM injection |
|
Aktív összehasonlító: Group 2 (the comparator group)
Pentaxim at 2, 4, 6, and 18 MoA, and the monovalent Hepatitis B vaccine at 1 and 6 MoA |
Pharmaceutical form:Freeze-dried PRP~T in a vial reconstituted with the injectable suspension of DTaP-IPV in a pre-filled syringe Route of administration:IM injection Pharmaceutical form: Depending on the brand procured Route of administration:IM injection |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
1 month after the last dose of primary series (investigational group [Hexaxim: Group 1] and comparator group [Pentaxim and monovalent Hep B: Group 2]) (7 MoA):
Időkeret: Day181
|
Anti-D Ab concentrations ≥0.1 IU/mL Anti-T Ab concentrations ≥0.1 IU/mL Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) Anti-PRP Ab concentrations ≥0.15 µg/mL Seroconversion for anti-PT and anti-FHA, defined as anti-PT and anti-FHA ≥4-fold Ab concentrations increase from pre-Dose 1 to 1 month post-Dose 3 Anti-Hep B Ab concentrations ≥10 mIU/mL GMC of PT and FHA |
Day181
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Baseline, pre-vaccination sample
Időkeret: Day 31
|
Ab concentrations/titers for each Ag Ab concentrations/titers above a cut-off:
|
Day 31
|
|
1 month after the last dose of primary series:
Időkeret: Day181
|
Ab concentrations/titers for each Ag Ab concentrations/titers above a cut-off:
|
Day181
|
|
Before the booster dose:
Időkeret: Day 511
|
Ab concentrations/titers for each Ag of Pentaxim and Hep B Ab concentrations/titers above a cut-off:
|
Day 511
|
|
1 month after the booster dose:
Időkeret: Day 541
|
Ab concentrations/titers for each Ag of Pentaxim Ab concentrations/titers above a cut-off:
|
Day 541
|
|
Presence of immediate unsolicited adverse events (AEs)
Időkeret: 30 minutes after each and any vaccination
|
30 minutes after each and any vaccination
|
|
|
Presence of solicited injection site reactions
Időkeret: for 8 days, including the day of each and any vaccination
|
(pre-listed in the participant diary and case report form [CRF]) |
for 8 days, including the day of each and any vaccination
|
|
Presence of solicited systemic reactions
Időkeret: for 8 days, including the day of each and any vaccination
|
(pre-listed in the participant diary and CRF) |
for 8 days, including the day of each and any vaccination
|
|
Presence of unsolicited AEs
Időkeret: for 30 days, including the day of each and any vaccination
|
for 30 days, including the day of each and any vaccination
|
|
|
Presence of serious adverse events (SAEs)
Időkeret: up to 12 months post last dose of vaccination in the primary series, and up to 1 month post booster vaccination
|
up to 12 months post last dose of vaccination in the primary series, and up to 1 month post booster vaccination
|
|
|
Presence of related SAEs and fatal case regardless of causality
Időkeret: Day 541
|
Day 541
|
|
|
Presence of AEs leading to study discontinuation
Időkeret: Day 541
|
Day 541
|
Együttműködők és nyomozók
Szponzor
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Becsült)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Egyéb vizsgálati azonosító számok
- A3L00054
- U1111-1227-3420 (Registry Identifier: ICTRP)
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
IPD terv leírása
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .